Stereotaxis to Participate in 20th Annual Craig-Hallum Institutional Investor Conference
Stereotaxis CEO David Fischel will participate in Craig-Hallum’s 20th Annual Institutional Investor Conference and will be available for one-on-one meetings with attendees. Fischel is excited to share Stereotaxis' technology, clinical value, and growth strategy with investors.
Positive
Stereotaxis CEO David Fischel will present Stereotaxis' differentiated technology, clinical value, and growth strategy to investors at Craig-Hallum’s 20th Annual Institutional Investor Conference.
05/25/2023 - 08:56 AM
ST. LOUIS, May 25, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in Craig-Hallum’s 20th Annual Institutional Investor Conference.
Mr. Fischel will be available on Wednesday, May 31, 2023 for one-on-one meetings with conference attendees.
“We appreciate the invitation by Craig-Hallum and look forward to sharing Stereotaxis’ differentiated technology, clinical value, and growth strategy with investors,” says Mr. Fischel.
About Stereotaxis Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com
What conference will Stereotaxis CEO be participating in?
Stereotaxis CEO David Fischel will be participating in Craig-Hallum’s 20th Annual Institutional Investor Conference.
What will David Fischel be sharing with investors at the conference?
David Fischel will be sharing Stereotaxis' differentiated technology, clinical value, and growth strategy with investors at the conference.
When will David Fischel be available for one-on-one meetings with conference attendees?
David Fischel will be available for one-on-one meetings with conference attendees on Wednesday, May 31, 2023.
STXS Rankings
#3509 Ranked by Stock Gains
STXS Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Tags
Medical Specialties, Health Technology, Manufacturing, Surgical and Medical Instrument Manufacturing
Country
US
City
St Louis
About STXS
stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. these innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. over 100 issued patents support the stereotaxis platform. the core components of stereotaxis’ systems have received regulatory clearance in the united states, european union, japan, canada, china, and elsewhere. for more information, please visit www.stereotaxis.com.
